Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
22.20
Dollar change
+0.47
Percentage change
2.16
%
Index- P/E34.33 EPS (ttm)0.65 Insider Own2.66% Shs Outstand302.79M Perf Week1.09%
Market Cap6.47B Forward P/E14.53 EPS next Y1.53 Insider Trans6.59% Shs Float283.54M Perf Month5.61%
Income205.05M PEG1.81 EPS next Q0.31 Inst Own88.07% Short Float3.67% Perf Quarter-7.19%
Sales1.85B P/S3.50 EPS this Y77.27% Inst Trans-2.04% Short Ratio5.30 Perf Half Y-6.88%
Book/sh7.21 P/B3.08 EPS next Y32.63% ROA6.90% Short Interest10.40M Perf Year16.78%
Cash/sh3.31 P/C6.71 EPS next 5Y19.00% ROE8.76% 52W Range18.64 - 24.34 Perf YTD-7.46%
Dividend Est.- P/FCF23.13 EPS past 5Y-21.77% ROI8.80% 52W High-8.79% Beta0.54
Dividend TTM- Quick Ratio3.41 Sales past 5Y17.31% Gross Margin95.70% 52W Low19.10% ATR (14)0.47
Dividend Ex-Date- Current Ratio3.46 EPS Y/Y TTM37.20% Oper. Margin11.07% RSI (14)57.25 Volatility1.60% 2.10%
Employees1310 Debt/Eq0.09 Sales Y/Y TTM10.98% Profit Margin11.10% Recom1.73 Target Price26.56
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q-0.49% Payout0.00% Rel Volume2.93 Prev Close21.73
Sales Surprise-7.77% EPS Surprise-47.04% Sales Q/Q4.02% EarningsApr 30 AMC Avg Volume1.96M Price22.20
SMA203.27% SMA500.99% SMA2000.78% Trades Volume5,749,158 Change2.16%
Date Action Analyst Rating Change Price Target Change
Apr-11-24Downgrade Barclays Overweight → Equal Weight $25
Dec-19-23Initiated BTIG Research Buy $27
Dec-15-23Initiated Citigroup Buy $31
Sep-26-23Initiated H.C. Wainwright Buy $28
Aug-22-23Reiterated Oppenheimer Outperform $25 → $29
Aug-08-23Initiated SVB Securities Market Perform $18
Jul-11-23Resumed Morgan Stanley Equal-Weight $21
May-10-23Resumed Piper Sandler Overweight $28
Mar-09-23Initiated Wells Fargo Overweight $23
Jan-26-23Initiated Credit Suisse Outperform $29
Jun-07-24 03:01AM
May-31-24 01:58PM
May-30-24 11:31AM
May-28-24 04:05PM
May-24-24 02:34AM
11:20AM Loading…
May-21-24 11:20AM
May-20-24 09:22AM
08:00AM
May-14-24 07:04PM
07:52AM
May-12-24 01:25PM
May-09-24 03:48PM
May-08-24 10:30AM
May-07-24 04:05PM
May-06-24 12:10PM
12:21PM Loading…
May-03-24 12:21PM
May-02-24 03:33PM
May-01-24 11:15AM
09:14AM
07:39AM
03:35AM
12:00AM
Apr-30-24 08:57PM
06:30PM
05:35PM
05:26PM
04:19PM
04:05PM
Apr-27-24 07:00AM
Apr-16-24 04:05PM
08:13AM Loading…
Mar-28-24 08:13AM
Mar-23-24 05:06AM
Mar-17-24 08:50AM
Mar-08-24 09:38AM
08:15AM
Mar-07-24 11:31AM
10:08AM
Mar-06-24 04:45PM
Mar-04-24 07:06PM
Mar-02-24 05:06AM
Feb-27-24 04:05PM
08:00AM
Feb-26-24 07:42AM
Feb-23-24 01:11PM
Feb-19-24 08:00AM
Feb-14-24 08:30AM
01:47AM
Feb-13-24 08:00AM
Feb-12-24 09:35AM
Feb-10-24 05:06AM
Feb-09-24 09:35AM
Feb-08-24 06:50PM
09:35AM
Feb-07-24 07:01PM
01:13PM
10:47AM
09:45AM
Feb-06-24 08:45PM
06:30PM
05:25PM
05:01PM
04:33PM
04:05PM
Feb-01-24 04:05PM
Jan-30-24 10:00AM
Jan-29-24 09:40AM
Jan-25-24 08:00AM
Jan-23-24 04:05PM
Jan-22-24 05:00PM
Jan-21-24 01:16PM
Jan-19-24 11:21AM
Jan-18-24 04:05PM
04:00PM
Jan-17-24 11:29AM
Jan-11-24 09:40AM
Jan-08-24 04:40PM
12:43PM
06:12AM
Jan-07-24 04:00PM
Jan-02-24 04:05PM
Dec-19-23 10:16AM
Dec-12-23 08:54AM
Dec-07-23 04:05PM
Dec-05-23 01:51PM
Dec-04-23 07:26PM
08:02AM
08:00AM
Dec-01-23 11:32AM
Nov-29-23 10:45AM
Nov-21-23 04:05PM
Nov-17-23 01:33PM
Nov-10-23 09:00AM
Nov-09-23 04:43PM
Nov-08-23 05:24PM
05:19AM
Nov-06-23 09:47AM
Nov-03-23 12:11PM
Nov-02-23 11:23AM
12:30AM
Nov-01-23 07:00PM
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WYSZOMIERSKI JACK LDirectorJun 04 '24Sale22.008,287182,314349,499Jun 06 08:37 PM
JOHNSON DAVID EDWARDDirectorMay 30 '24Buy20.76225,0004,670,0551,525,730May 30 07:50 PM
JOHNSON DAVID EDWARDDirectorMay 28 '24Buy20.32200,0004,063,9001,300,730May 30 07:50 PM
POSTE GEORGEDirectorMay 21 '24Option Exercise19.5711,686228,695225,593May 22 07:23 PM
Smith JulieDirectorMay 21 '24Sale21.1227,280576,1545,445May 23 06:55 PM
POSTE GEORGEDirectorMay 21 '24Sale20.9611,686244,939213,907May 22 07:23 PM
PAPADOPOULOS STELIOSDirectorMay 20 '24Option Exercise19.5711,686228,6951,272,015May 22 07:23 PM
PAPADOPOULOS STELIOSDirectorMay 20 '24Sale21.0011,437240,1771,260,578May 22 07:23 PM
WYSZOMIERSKI JACK LDirectorMay 13 '24Option Exercise19.5711,686228,695349,871May 15 07:44 PM
WYSZOMIERSKI JACK LDirectorMay 13 '24Sale21.3710,923233,425338,948May 15 07:44 PM
Garber Alan MDirectorMar 21 '24Option Exercise19.5723,491459,71954,908Mar 25 07:31 PM
Garber Alan MDirectorMar 21 '24Sale24.0119,205461,11235,703Mar 25 07:31 PM
Haley Patrick J.EVP, CommercialFeb 23 '24Sale21.4547,0201,008,579384,866Feb 27 06:58 PM
JOHNSON DAVID EDWARDDirectorFeb 21 '24Buy20.70190,0003,932,7341,100,730Feb 22 05:08 PM
Haley Patrick J.EVP, CommercialDec 14 '23Option Exercise16.2950,000814,500357,687Dec 14 07:56 PM
Haley Patrick J.EVP, CommercialDec 14 '23Sale23.3550,0001,167,500307,687Dec 14 07:56 PM
Hessekiel JeffreyEVP, General Counsel & SecDec 13 '23Sale23.0125,000575,250533,345Dec 14 07:55 PM
Haley Patrick J.EVP, CommercialDec 12 '23Sale22.5014,149318,352307,687Dec 14 07:56 PM
Hessekiel JeffreyEVP, General Counsel & SecDec 04 '23Sale22.0625,000551,500558,345Dec 04 06:22 PM
Hessekiel JeffreyEVP, General Counsel & SecNov 30 '23Sale22.0125,000550,250583,345Dec 04 06:22 PM
JOHNSON DAVID EDWARDDirectorNov 27 '23Buy21.61120,4092,602,038910,730Nov 29 04:30 PM
JOHNSON DAVID EDWARDDirectorNov 27 '23Sale21.61120,4092,602,038790,321Nov 29 04:30 PM
Aftab DanaCSO/EVP Disc & Trans ResearchAug 30 '23Sale22.474,600103,362399,943Sep 01 08:15 PM
MORRISSEY MICHAELPresident and CEOAug 28 '23Option Exercise15.31360,0005,511,600945,496Aug 30 09:48 PM
Senner Christopher J.EVP and CFOAug 04 '23Option Exercise14.7460,000884,400631,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 04 '23Sale20.6860,0001,240,800571,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 03 '23Option Exercise14.7460,000884,400631,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 03 '23Sale20.5160,0001,230,600571,631Aug 07 09:20 PM
Haley Patrick J.EVP, CommercialAug 03 '23Sale20.6730,553631,531285,467Aug 07 08:24 PM
Hessekiel JeffreyEVP, General Counsel & SecAug 01 '23Option Exercise14.7455,710821,165627,686Aug 03 08:02 PM
Hessekiel JeffreyEVP, General Counsel & SecAug 01 '23Sale19.6355,7101,093,587571,976Aug 03 08:02 PM